VanEck Pharmaceutical ETFPPH
PPH
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $694K
18% more capital invested
Capital invested by funds: $459M [Q2] → $540M (+$81M) [Q3]
16% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 43
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1% less funds holding
Funds holding: 137 [Q2] → 136 (-1) [Q3]
1.82% less ownership
Funds ownership: 76.66% [Q2] → 74.85% (-1.82%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for PPH.
Financial journalist opinion
Based on 3 articles about PPH published over the past 30 days
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund launched on 12/20/2011.
Positive
Seeking Alpha
2 weeks ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
CNBC Television
3 weeks ago
Final Trade: MSTR, PPH, TLT, MCD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Positive
ETF Trends
1 month ago
PPH Is a Pertinent Healthcare Idea for 2025
The healthcare sector is conspicuous in its absence from this year's bull market for stocks. As of Dec. 17, the S&P Health Care Select Sector Index was higher by just 3.2% since the start of the year compared to a 28.3% gain for the S&P 500.
Neutral
Zacks Investment Research
2 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Negative
Seeking Alpha
4 months ago
Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH
The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high price-to-earnings ratio and concentrated portfolio, particularly in top holdings like LLY and NVO. Technical indicators suggest bearish momentum, with potential support in the mid-$80s, making it a favorable risk/reward buy on further pullback.
Positive
ETF Trends
4 months ago
Healthcare ETFs Starting to Look Healthy
The healthcare sector hasn't been a bad performer, per se. Year-to-date, the S&P Health Care Select Sector Index is up 13.1%, but that lags the S&P 500 by 800 basis points, confirming investors have cause to be frustrated with blue-chip pharmaceuticals and biotechnology equities.
Neutral
ETF Trends
4 months ago
DoubleLine's Jeff Gundlach on the Fed, Gold and Private Credit
Blurring the lines between conference and festival, this year's Future Proof brought thousands of attendees to the summery shores of Huntington Beach in Los Angeles.
Neutral
Zacks Investment Research
4 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.
Positive
ETF Trends
4 months ago
This Pharma ETF Could Be Ideal Healthcare Pick
Broadly speaking, the healthcare sector remains a laggard relative to the broader market. As of Aug. 28, the S&P Select Sector Health Care Index was trailing the S&P 500 by 310 basis points on a year-to-date basis.
Charts implemented using Lightweight Charts™